First bioequivalence studies used to
treat Covid-19 in Turkey
has been started with the partnership of
Gaziantep University
Farmagen GCP Center
and
Novagenix Bioanalytical Drug R&D Center.
First bioequivalence studies used to
treat Covid-19 in Turkey
has been started with the partnership of
Gaziantep University
Farmagen GCP Center
and
Novagenix Bioanalytical Drug R&D Center.
Bioequivalence study was approved for the Favipiravir active ingredient
used in the treatment of COVID-19
has been approved by
Ethics Committee
and
Ministry of Health-TITCK.
Novagenix is now 23 years old.
Bioanalytical Laboratory has been renewed.
We do yes/no analysis on all types of samples.
